UA41667C2 - Antiseptic - Google Patents

Abstract

The invention relates to the medicine, in particular to the antiseptics used for preventing and treating diseases, especially the venereal ones. The antiseptic represents the solution of the surface-active substance comprising benzyldimethyl [3-(miristoylamine) propyl] ammonium chloride monohydrate – 0.1 g and the purified water – to 1000 g.

Description

The antimicrobial effect of BM solutions on cultures, which are most often detected in sinusitis of microorganisms, was studied on solid nutrient media by the "well" method (N.M. Datsenko, 1989). The results presented in Table 1 indicate a higher antimicrobial activity of 0.0195 BM solution compared to 0.0295 HC solution.

Example 2. Table 2 shows a comparative analysis of the results of treatment of patients with infected wounds and trophic ulcers of the lower extremities with 0.0195 BM solution and 0.0295 XH solution.

Table 2 11111111 Research methods.//7/:.//:./Z | BM | 7 | HER 11111111 | line of treatment// | | Time-limit treatment inspiration day 2. Dynamic leukocytosis 86 | 70 | 67 | 85 | 8 | 7

Z. Plodaranvsm" 77777777 | 86 | 80 | 67 | 81 | 79 | 75

Example 3. Table C shows a comparative analysis of the results of treatment and the average length of stay of patients in the hospital.

Table C 11111111 Indicators. HER 77777 BM HER ЖгССсСшС rejection 2905 rejection 1595

The results, shown in Tables 2 and 3, indicate a higher efficiency of BM compared to HC in the treatment of purulent wounds and trophic ulcers of the extremities in the first phase of the wound process. The use of BM made it possible to reduce the microbial number and microbial seeding of wounds and ulcers, which contributes to the rapid cleansing of wounds, the appearance of granulations and marginal epithelization.

The results of skin plastic surgery and conservative treatment when using BM are better than when using HG.

Example 4. Table 4 shows the results of the treatment of patients with spilled peritonitis with the inclusion in the treatment complex of 0.0195 BM solution and 0.0295 XH solution

Table 4 with 11111111 indicators///////

Eventration 7 Y7777171117 1711155 |111712 |. 66 2

Abscess of abdominal cavity - | - | 2 | 66

Intestinal fistula o/z (Lethality. 1111vo 71117111

Note: The number of patients who died from progressive peritonitis is indicated in parentheses.

The use of BM in the complex of treatment of peritonitis contributes to shortening the treatment period of patients by 7.7 beds/days, reducing postoperative mortality and reducing the number of postoperative purulent-inflammatory complications.

Example 5. Table 5 shows the speed of mucociliary transport in patients with sinusitis in the dynamics of treatment.

Table 5 tons | what an elephant you are

Drug Time of investigation of sinusitis, MET of patients - --- nya i - -----

BM | 71 | Treatment 214503 | 2933405 | with 31,550.3 | 353306

NI PI Zh sia di Pii Noi Pi beginning of treatment 77777117 |Final treatment| 154502 | 160303 | 1813404 | 18403 7177 shiv i ry) VMyo VEK of the beginning of treatment 77777717 | Final treatment 172503 | 212506 | 252503 | 242503

Example 6. Table b shows the number of colony-forming units in 1 ml (CFU/ml) of experimental material in patients with sinusitis in the course of treatment.

Table 6 preparation of sinusitis research patients, MET

PNYA PNYA PNYA POLYA PRYE polypous

ME YOU On the day from the start of treatment

MON THURSDAY PO POL oo THURSDAY NOV NO treatment 77777711 |Treatment| 2409385 | 59275212 | 62515298

NO PI EE PON NO KAN from the beginning of treatment

MON MON B MON aso IT IS NNYA BUT treatment

Example 7. Table 7 shows the average deviations from the norm of immunity indicators at the end of treatment (for 10095, the deviation at the beginning of treatment is taken).

Table 7

BM 11111111

Example 8. Table 8 shows the indicators of the level of eosinophilia in the dynamics of treatment of patients with allergic sinusitis.

Table 8 of patients 11111111. 1

Initial call | Isolated from the cavity of the 84th 13 39 | 82 11111111 Sinus//// | 77777777 7 | 251 M | 18

BNO NOV Bin NNYA WMO Airborne Forces PSHAYA starting treatment 77777711 1771717111111|11Vmistpazuh,///7// | 77777777 7 | 7 | tho | 5 77771111 11 Khs 3 | 7 | 10 77111111 Sinus///7// | 77777777 / | 5 | at

Final treatment BM ) | Separated from the cavity | 32 | 21 | 9 | 2 17111111 Content crawler////// | 77777777 | 18 2 | 2 77777171 11 ХС |Separated from the cavitinosai////// 19 4 | 8 | 9 | 2 77777771 177171717111111|177Vmistpazuh/77/7/ДГ/ | 77777777 / | 7 | 8 | 4

The effect of 0.0195 BM solution does not inhibit the transport function of the ciliated epithelium of the mucous membrane of the nasal cavity in healthy people and patients with various forms of sinusitis.

The use of BM contributes to a more pronounced normalization of the investigated indicators of immunity in patients with chronic sinusitis than the solution of HC (tables 5, 6, 7, 8).

Example 9. Table 9 shows the changes in immunological parameters in patients with chronic urethroprostatitis during the treatment of BM and HG.

Table 9 control group of 3331 women in NN combined with BM combined with HG

Note: E-ROC - E rosette-forming cells, FP - phagocytic index, ФЧ - phagocytic number,

NetT-test - nitroso-blue tetrazole test. The number in parentheses is immunological indicators before treatment.

Example 10. Table 10 shows the effectiveness of treatment of patients with chronic and torpid gonorrheal urethritis.

Table 10

Symptoms of the disease Time of normalization of the symptoms of the disease in patients with urethritis (in days) sleep 333 veins Dnvite t ME received BM (p-:61) | received CG (n: 58 differences (R

Example 11. Table 11 shows the indicators of the effectiveness of treatment of patients with trichomonas urethritis.

Table 11 days of settlement 3333 nee Me received BM (p-33)| received CG (p-20) differences (P)

The inclusion of 0.0195 BM solution in the complex therapy of urethritis and urethroprostatitis of various etiologies leads to faster normalization of immunological and clinical indicators in patients than when using 0.0295 HG solution (tables 9, 10, 11).

Antiseptic agent BM according to the invention has a high antibacterial activity, which is much more pronounced compared to such commonly used antiseptic agents as iodovidone, furacilin, chlorhexidine, rokal, hydrogen peroxide solution, polymeric preparations of iodine, nitrofuran antiseptics, etonium, dekamethoxine, octenisept, has a wide range of clinical applications; is not toxic; it has no side effects and contraindications; has an immunostimulating effect; activates repair processes; reduces the resistance of microorganisms to antibiotics; reduces recovery time.

BM has an immunoadjuvant effect, strengthens local protective reactions, regeneration processes due to the modulation of cellular and local humoral response, has no local irritating effect and allergenic properties, no teratogenic, embryotoxic effects have been detected. The drug has no carcinogenic and mutagenic properties.